Noubar Afeyan - Net Worth and Insider Trading

Noubar Afeyan Net Worth

The estimated net worth of Noubar Afeyan is at least $294 Million dollars as of 2024-12-27. Noubar Afeyan is the Director of Moderna Inc and owns about 6,856,164 shares of Moderna Inc (MRNA) stock worth over $275 Million. Noubar Afeyan is the Director, 10% Owner of Seres Therapeutics Inc and owns about 21,586,905 shares of Seres Therapeutics Inc (MCRB) stock worth over $19 Million. Noubar Afeyan is also the Director, 10% Owner of BG Medicine Inc and owns about 1,286,274 shares of BG Medicine Inc (BGMD) stock worth over $129. Details can be seen in Noubar Afeyan's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Noubar Afeyan has not made any transactions after 2024-07-31 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Noubar Afeyan

Noubar Afeyan Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Noubar Afeyan owns 27 companies in total, including Foghorn Therapeutics Inc (FHTX) , Codiak BioSciences Inc (CDAKQ) , and Moderna Inc (MRNA) among others .

Click here to see the complete history of Noubar Afeyan’s form 4 insider trades.

Insider Ownership Summary of Noubar Afeyan

Ticker	Comapny	Transaction Date	Type of Owner
FHTX	Foghorn Therapeutics Inc	2020-10-22	10 percent owner
CDAKQ	Codiak BioSciences Inc	2020-10-13	10 percent owner
MRNA	Moderna Inc	2024-07-31	director & 10 percent owner
		2018-05-08	director & 10 percent owner
		2019-02-27	director & 10 percent owner
		2021-03-19	director & 10 percent owner
		2020-05-18	10 percent owner
		2019-05-01	10 percent owner
		2019-06-18	director
		2017-08-17	10 percent owner
		2017-12-07	10 percent owner
		2017-12-06	10 percent owner
		2016-09-06	10 percent owner
		2016-08-11	10 percent owner
		2016-06-21	director & 10 percent owner
		2015-12-09	director & 10 percent owner
		2014-08-06	10 percent owner
		2013-07-23	10 percent owner
		2014-02-12	10 percent owner
		2013-09-25	director & 10 percent owner
		2013-09-18	10 percent owner
		2013-03-25	10 percent owner
		2004-05-27	director
		2021-02-03	10 percent owner
		2020-12-03	10 percent owner
		2021-07-29	director & 10 percent owner
		2016-09-06	10 percent owner

Noubar Afeyan Latest Holdings Summary

Noubar Afeyan currently owns a total of 3 stocks. Among these stocks, Noubar Afeyan owns 6,856,164 shares of Moderna Inc (MRNA) as of July 31, 2024, with a value of $275 Million and a weighting of 93.49%. Noubar Afeyan owns 21,586,905 shares of Seres Therapeutics Inc (MCRB) as of June 18, 2019, with a value of $19 Million and a weighting of 6.51%. Noubar Afeyan also owns 1,286,274 shares of BG Medicine Inc (BGMD) as of December 9, 2015, with a value of $129 and a weighting of 0%.

Latest Holdings of Noubar Afeyan

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
MRNA	Moderna Inc	2024-07-31	6,856,164	40.13	275,137,861
MCRB	Seres Therapeutics Inc	2019-06-18	21,586,905	0.89	19,143,267
BGMD	BG Medicine Inc	2015-12-09	1,286,274	0.00	129

Holding Weightings of Noubar Afeyan

Noubar Afeyan Form 4 Trading Tracker

According to the SEC Form 4 filings, Noubar Afeyan has made a total of 85 transactions in Moderna Inc (MRNA) over the past 5 years, including 0 buys and 85 sells. The most-recent trade in Moderna Inc is the sale of 15,000 shares on July 31, 2024, which brought Noubar Afeyan around $2 Million.

According to the SEC Form 4 filings, Noubar Afeyan has made a total of 0 transactions in Seres Therapeutics Inc (MCRB) over the past 5 years. The most-recent trade in Seres Therapeutics Inc is the acquisition of 8,888,888 shares on June 18, 2019, which cost Noubar Afeyan around $20 Million.

According to the SEC Form 4 filings, Noubar Afeyan has made a total of 0 transactions in BG Medicine Inc (BGMD) over the past 5 years. The most-recent trade in BG Medicine Inc is the sale of 46,438 shares on December 9, 2015, which brought Noubar Afeyan around $26,005.

Insider Trading History of Noubar Afeyan

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Noubar Afeyan Trading Performance

GuruFocus tracks the stock performance after each of Noubar Afeyan's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Noubar Afeyan is 46.36%. GuruFocus also compares Noubar Afeyan's trading performance to market benchmark return within the same time period. The performance of stocks bought by Noubar Afeyan within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Noubar Afeyan's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Noubar Afeyan

Average Return

Average return per transaction

Outperforming Transactions

1 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	20.31
Relative Return to S&P 500(%)	17.66

Noubar Afeyan Ownership Network

Ownership Network List of Noubar Afeyan

No Data

Ownership Network Relation of Noubar Afeyan

Noubar Afeyan Owned Company Details

What does Foghorn Therapeutics Inc do?

Who are the key executives at Foghorn Therapeutics Inc?

Noubar Afeyan is the 10 percent owner of Foghorn Therapeutics Inc. Other key executives at Foghorn Therapeutics Inc include Chief People Officer Carlos Costa , See Remarks Steven F. Bellon , and Chief Strategy/Bus Ops Officer Fanny Cavalie .

Foghorn Therapeutics Inc (FHTX) Insider Trades Summary

Over the past 18 months, Noubar Afeyan made no insider transaction in Foghorn Therapeutics Inc (FHTX). Other recent insider transactions involving Foghorn Therapeutics Inc (FHTX) include a net sale of 58,859 shares made by Carlos Costa , a net sale of 311,297 shares made by Samuel Agresta , and a net sale of 20,000 shares made by Steven F. Bellon .

In summary, during the past 3 months, insiders sold 0 shares of Foghorn Therapeutics Inc (FHTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 401,156 shares of Foghorn Therapeutics Inc (FHTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 401,156 shares.

Foghorn Therapeutics Inc (FHTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Foghorn Therapeutics Inc Insider Transactions

No Available Data

What does Codiak BioSciences Inc do?

Who are the key executives at Codiak BioSciences Inc?

Noubar Afeyan is the 10 percent owner of Codiak BioSciences Inc. Other key executives at Codiak BioSciences Inc include See Remarks Yalonda Howze , Chief Scientific Officer Sriram Sathyanarayanan , and See Remarks Nicole Barna .

Codiak BioSciences Inc (CDAKQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Codiak BioSciences Inc (CDAKQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Codiak BioSciences Inc (CDAKQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Codiak BioSciences Inc (CDAKQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Codiak BioSciences Inc Insider Transactions

No Available Data

What does Moderna Inc do?

Who are the key executives at Moderna Inc?

Noubar Afeyan is the director & 10 percent owner of Moderna Inc. Other key executives at Moderna Inc include Chief Legal Officer Shannon Thyme Klinger , President Stephen Hoge , and Chief Financial Officer James M Mock .

Moderna Inc (MRNA) Insider Trades Summary

Over the past 18 months, Noubar Afeyan made 38 insider transaction in Moderna Inc (MRNA) with a net sale of 742,832. Other recent insider transactions involving Moderna Inc (MRNA) include a net sale of 199,642 shares made by Stephen Hoge , a net sale of 13,661 shares made by Shannon Thyme Klinger , and a net sale of 10,811 shares made by James M Mock .

In summary, during the past 3 months, insiders sold 5,076 shares of Moderna Inc (MRNA) in total and bought 0 shares, with a net sale of 5,076 shares. During the past 18 months, 1,021,026 shares of Moderna Inc (MRNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,021,026 shares.

Moderna Inc (MRNA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Moderna Inc Insider Transactions

No Available Data

What does Evelo Biosciences Inc do?

Who are the key executives at Evelo Biosciences Inc?

Noubar Afeyan is the director & 10 percent owner of Evelo Biosciences Inc. Other key executives at Evelo Biosciences Inc include Chief Medical Officer Duncan Mchale , See Remarks Mark Bodmer , and Chief Financial Officer Marella Thorell .

Evelo Biosciences Inc (EVLO) Insider Trades Summary

Over the past 18 months, Noubar Afeyan made no insider transaction in Evelo Biosciences Inc (EVLO). Other recent insider transactions involving Evelo Biosciences Inc (EVLO) include a net sale of 13,391 shares made by Duncan Mchale , a net sale of 13,145 shares made by Mark Bodmer , and a net sale of 7,814 shares made by Marella Thorell .

In summary, during the past 3 months, insiders sold 0 shares of Evelo Biosciences Inc (EVLO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 36,860 shares of Evelo Biosciences Inc (EVLO) were sold and 5,411,255 shares were bought by its insiders, resulting in a net purchase of 5,374,395 shares.

Evelo Biosciences Inc (EVLO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Evelo Biosciences Inc Insider Transactions

No Available Data

What does Kaleido Biosciences Inc do?

Who are the key executives at Kaleido Biosciences Inc?

Noubar Afeyan is the director & 10 percent owner of Kaleido Biosciences Inc. Other key executives at Kaleido Biosciences Inc include Chief Medical Officer Alison S Long , Chief Scientific Officer Van Hylckama Vlieg Johan , and director & Chief Executive Officer Daniel L Menichella .

Kaleido Biosciences Inc (KLDO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Kaleido Biosciences Inc (KLDO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Kaleido Biosciences Inc (KLDO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Kaleido Biosciences Inc (KLDO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kaleido Biosciences Inc Insider Transactions

No Available Data

What does Rubius Therapeutics Inc do?

Who are the key executives at Rubius Therapeutics Inc?

Noubar Afeyan is the director & 10 percent owner of Rubius Therapeutics Inc. Other key executives at Rubius Therapeutics Inc include CEO and President Dannielle Appelhans , director & Chief Executive Officer Pablo J Cagnoni , and Chief Scientific Officer Laurence A. Turka .

Rubius Therapeutics Inc (RUBY) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Rubius Therapeutics Inc (RUBY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Rubius Therapeutics Inc (RUBY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Rubius Therapeutics Inc (RUBY)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rubius Therapeutics Inc Insider Transactions

No Available Data

What does Axcella Health Inc do?

Who are the key executives at Axcella Health Inc?

Noubar Afeyan is the 10 percent owner of Axcella Health Inc. Other key executives at Axcella Health Inc include Senior Vice President & CIPO Paul Fehlner , director & President and CEO William Hinshaw , and 10 percent owner L.p. Fpa, .

Axcella Health Inc (AXLA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Axcella Health Inc (AXLA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Axcella Health Inc (AXLA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Axcella Health Inc (AXLA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Axcella Health Inc Insider Transactions

No Available Data

What does TransMedics Group Inc do?

Who are the key executives at TransMedics Group Inc?

Noubar Afeyan is the 10 percent owner of TransMedics Group Inc. Other key executives at TransMedics Group Inc include Chief Commercial Officer Tamer I Khayal , director & President & CEO Waleed H Hassanein , and See Remarks Nicholas Corcoran .

TransMedics Group Inc (TMDX) Insider Trades Summary

Over the past 18 months, Noubar Afeyan made no insider transaction in TransMedics Group Inc (TMDX). Other recent insider transactions involving TransMedics Group Inc (TMDX) include a net sale of 237,070 shares made by Tamer I Khayal , a net sale of 256,194 shares made by Waleed H Hassanein , and a net sale of 88,963 shares made by Stephen Gordon .

In summary, during the past 3 months, insiders sold 21,958 shares of TransMedics Group Inc (TMDX) in total and bought 0 shares, with a net sale of 21,958 shares. During the past 18 months, 710,416 shares of TransMedics Group Inc (TMDX) were sold and 2,500 shares were bought by its insiders, resulting in a net sale of 707,916 shares.

TransMedics Group Inc (TMDX)'s detailed insider trading history can be found in Insider Trading Tracker table.

TransMedics Group Inc Insider Transactions

No Available Data

What does Seres Therapeutics Inc do?

Who are the key executives at Seres Therapeutics Inc?

Noubar Afeyan is the director of Seres Therapeutics Inc. Other key executives at Seres Therapeutics Inc include Chief Scientific Officer Matthew R. Henn , CFO and EVP Eric D. Shaff , and See Remarks Thomas Desrosier .

Seres Therapeutics Inc (MCRB) Insider Trades Summary

Over the past 18 months, Noubar Afeyan made no insider transaction in Seres Therapeutics Inc (MCRB). Other recent insider transactions involving Seres Therapeutics Inc (MCRB) include a net sale of 35,910 shares made by Teresa L. Young , a net sale of 36,307 shares made by Eric D. Shaff , and a net sale of 15,855 shares made by Moltke Lisa Von .

In summary, during the past 3 months, insiders sold 30,330 shares of Seres Therapeutics Inc (MCRB) in total and bought 0 shares, with a net sale of 30,330 shares. During the past 18 months, 140,004 shares of Seres Therapeutics Inc (MCRB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 140,004 shares.

Seres Therapeutics Inc (MCRB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Seres Therapeutics Inc Insider Transactions

No Available Data

What does Syros Pharmaceuticals Inc do?

Who are the key executives at Syros Pharmaceuticals Inc?

Noubar Afeyan is the 10 percent owner of Syros Pharmaceuticals Inc. Other key executives at Syros Pharmaceuticals Inc include director & 10 percent owner & President & CEO Nancy A Simonian , Chief Legal Officer Gerald E Quirk , and Chief Development Officer Kristin Stephens .

Syros Pharmaceuticals Inc (SYRS) Insider Trades Summary

Over the past 18 months, Noubar Afeyan made no insider transaction in Syros Pharmaceuticals Inc (SYRS). Other recent insider transactions involving Syros Pharmaceuticals Inc (SYRS) include a net sale of 42,622 shares made by David Roth , a net sale of 171,783 shares made by Nancy A Simonian , and a net sale of 37,803 shares made by Jason Haas .

In summary, during the past 3 months, insiders sold 539,272 shares of Syros Pharmaceuticals Inc (SYRS) in total and bought 0 shares, with a net sale of 539,272 shares. During the past 18 months, 570,484 shares of Syros Pharmaceuticals Inc (SYRS) were sold and 1,104,977 shares were bought by its insiders, resulting in a net purchase of 534,493 shares.

Syros Pharmaceuticals Inc (SYRS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Syros Pharmaceuticals Inc Insider Transactions

No Available Data

What does Denali Therapeutics Inc do?

Who are the key executives at Denali Therapeutics Inc?

Noubar Afeyan is the 10 percent owner of Denali Therapeutics Inc. Other key executives at Denali Therapeutics Inc include COO and Secretary Alexander O. Schuth , director & President and CEO Ryan J. Watts , and CFO and Treasurer Steve E. Krognes .

Denali Therapeutics Inc (DNLI) Insider Trades Summary

Over the past 18 months, Noubar Afeyan made no insider transaction in Denali Therapeutics Inc (DNLI). Other recent insider transactions involving Denali Therapeutics Inc (DNLI) include a net sale of 29,606 shares made by Vicki L Sato , a net sale of 89,326 shares made by Alexander O. Schuth , and a net sale of 54,249 shares made by Carole Ho .

In summary, during the past 3 months, insiders sold 149,099 shares of Denali Therapeutics Inc (DNLI) in total and bought 0 shares, with a net sale of 149,099 shares. During the past 18 months, 478,357 shares of Denali Therapeutics Inc (DNLI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 478,357 shares.

Denali Therapeutics Inc (DNLI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Denali Therapeutics Inc Insider Transactions

No Available Data

What does Quanterix Corp do?

Who are the key executives at Quanterix Corp?

Noubar Afeyan is the 10 percent owner of Quanterix Corp. Other key executives at Quanterix Corp include President & Quanterix & Dx Masoud Toloue , Chief Financial Officer Vandana Sriram , and CFO and Treasurer Michael A Doyle .

Quanterix Corp (QTRX) Insider Trades Summary

Over the past 18 months, Noubar Afeyan made no insider transaction in Quanterix Corp (QTRX). Other recent insider transactions involving Quanterix Corp (QTRX) include a net sale of 5,500 shares made by Laurie J Olson , a net purchase of 47,000 shares made by David R Walt , and a net purchase of 20,200 shares made by William P Donnelly .

In summary, during the past 3 months, insiders sold 0 shares of Quanterix Corp (QTRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 5,500 shares of Quanterix Corp (QTRX) were sold and 86,200 shares were bought by its insiders, resulting in a net purchase of 80,700 shares.

Quanterix Corp (QTRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Quanterix Corp Insider Transactions

No Available Data

What does Sesen Bio Inc do?

Who are the key executives at Sesen Bio Inc?

Noubar Afeyan is the 10 percent owner of Sesen Bio Inc. Other key executives at Sesen Bio Inc include 10 percent owner Modernatx, Inc. , Chief Scientific Officer Michael Klichinsky , and director & President and CEO Steven Kelly .

Sesen Bio Inc (SESN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sesen Bio Inc (SESN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sesen Bio Inc (SESN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sesen Bio Inc (SESN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sesen Bio Inc Insider Transactions

No Available Data

What does Editas Medicine Inc do?

Who are the key executives at Editas Medicine Inc?

Noubar Afeyan is the 10 percent owner of Editas Medicine Inc. Other key executives at Editas Medicine Inc include SVP & CHIEF MEDICAL OFFICER Baisong Mei , director & CEO Gilmore Neil O'neill , and EVP & CHIEF SCIENTIFIC OFFICER Linda Burkly .

Editas Medicine Inc (EDIT) Insider Trades Summary

Over the past 18 months, Noubar Afeyan made no insider transaction in Editas Medicine Inc (EDIT). Other recent insider transactions involving Editas Medicine Inc (EDIT) include a net sale of 32,833 shares made by Baisong Mei , a net sale of 1,883 shares made by Bruce Eaton , and a net sale of 93,188 shares made by Gilmore Neil O'neill .

In summary, during the past 3 months, insiders sold 2,159 shares of Editas Medicine Inc (EDIT) in total and bought 0 shares, with a net sale of 2,159 shares. During the past 18 months, 162,127 shares of Editas Medicine Inc (EDIT) were sold and 45,000 shares were bought by its insiders, resulting in a net sale of 117,127 shares.

Editas Medicine Inc (EDIT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Editas Medicine Inc Insider Transactions

No Available Data

What does Cartesian Therapeutics Inc do?

Who are the key executives at Cartesian Therapeutics Inc?

Noubar Afeyan is the director & 10 percent owner of Cartesian Therapeutics Inc. Other key executives at Cartesian Therapeutics Inc include Chief Medical Officer Peter G Traber , director & President & CEO Carsten Brunn , and Chief Scientific Officer Takashi Kei Kishimoto .

Cartesian Therapeutics Inc (RNAC) Insider Trades Summary

Over the past 18 months, Noubar Afeyan made no insider transaction in Cartesian Therapeutics Inc (RNAC). Other recent insider transactions involving Cartesian Therapeutics Inc (RNAC) include a net purchase of 1,921,182 shares made by Timothy A Springer , a net sale of 52,115 shares made by , and a net purchase of 7,500 shares made by Timothy C Barabe .

In summary, during the past 3 months, insiders sold 241,836 shares of Cartesian Therapeutics Inc (RNAC) in total and bought 689,850 shares, with a net purchase of 448,014 shares. During the past 18 months, 241,957 shares of Cartesian Therapeutics Inc (RNAC) were sold and 746,143 shares were bought by its insiders, resulting in a net purchase of 504,186 shares.

Cartesian Therapeutics Inc (RNAC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cartesian Therapeutics Inc Insider Transactions

No Available Data

What does BG Medicine Inc do?

Who are the key executives at BG Medicine Inc?

Noubar Afeyan is the director & 10 percent owner of BG Medicine Inc. Other key executives at BG Medicine Inc include 10 percent owner Flagship Pioneering Inc. , 10 percent owner Agtc Advisors Fund Lp , and 10 percent owner Applied Genomic Technology Capital Fund Lp .

BG Medicine Inc (BGMD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of BG Medicine Inc (BGMD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of BG Medicine Inc (BGMD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

BG Medicine Inc (BGMD)'s detailed insider trading history can be found in Insider Trading Tracker table.

BG Medicine Inc Insider Transactions

No Available Data

What does T2 Biosystems Inc do?

Who are the key executives at T2 Biosystems Inc?

Noubar Afeyan is the 10 percent owner of T2 Biosystems Inc. Other key executives at T2 Biosystems Inc include 10 percent owner Cr Group L.p. , 10 percent owner Crg Partners Iii (cayman) Unlev Aiv I L.p. , and 10 percent owner Crg Partners Iii (cayman) Lev Aiv I L.p. .

T2 Biosystems Inc (TTOO) Insider Trades Summary

Over the past 18 months, Noubar Afeyan made no insider transaction in T2 Biosystems Inc (TTOO). Other recent insider transactions involving T2 Biosystems Inc (TTOO) include a net sale of 48,345,798 shares made by Cr Group L.p. , and a net sale of 55 shares made by David B Elsbree .

In summary, during the past 3 months, insiders sold 0 shares of T2 Biosystems Inc (TTOO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 483,513 shares of T2 Biosystems Inc (TTOO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 483,513 shares.

T2 Biosystems Inc (TTOO)'s detailed insider trading history can be found in Insider Trading Tracker table.

T2 Biosystems Inc Insider Transactions

No Available Data

What does Agios Pharmaceuticals Inc do?

Who are the key executives at Agios Pharmaceuticals Inc?

Noubar Afeyan is the 10 percent owner of Agios Pharmaceuticals Inc. Other key executives at Agios Pharmaceuticals Inc include Principal Accounting Officer Washburn Theodore James Jr. , Chief Legal Officer James William Burns , and Chief Financial Officer Cecilia Jones .

Agios Pharmaceuticals Inc (AGIO) Insider Trades Summary

Over the past 18 months, Noubar Afeyan made no insider transaction in Agios Pharmaceuticals Inc (AGIO). Other recent insider transactions involving Agios Pharmaceuticals Inc (AGIO) include a net sale of 10,188 shares made by Washburn Theodore James Jr. , a net sale of 35,912 shares made by James William Burns , and a net sale of 64,534 shares made by Brian Goff .

In summary, during the past 3 months, insiders sold 42,724 shares of Agios Pharmaceuticals Inc (AGIO) in total and bought 0 shares, with a net sale of 42,724 shares. During the past 18 months, 295,320 shares of Agios Pharmaceuticals Inc (AGIO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 295,320 shares.

Agios Pharmaceuticals Inc (AGIO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Agios Pharmaceuticals Inc Insider Transactions

No Available Data

What does Concert Pharmaceuticals Inc do?

Who are the key executives at Concert Pharmaceuticals Inc?

Noubar Afeyan is the 10 percent owner of Concert Pharmaceuticals Inc. Other key executives at Concert Pharmaceuticals Inc include Chief Development Officer James V Cassella , CFO & PFO Marc A. Becker , and Chief Operating Officer Nancy Stuart .

Concert Pharmaceuticals Inc (CNCE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Concert Pharmaceuticals Inc (CNCE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Concert Pharmaceuticals Inc (CNCE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Concert Pharmaceuticals Inc (CNCE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Concert Pharmaceuticals Inc Insider Transactions

No Available Data

What does DNIB Unwind Inc do?

Who are the key executives at DNIB Unwind Inc?

Noubar Afeyan is the director & 10 percent owner of DNIB Unwind Inc. Other key executives at DNIB Unwind Inc include director & other: Chairman Daniel Lynch , Chief Scientific Officer Jonathan Michael Yingling , and director & PRESIDENT & CEO Andrew Hirsch .

DNIB Unwind Inc (BINDQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of DNIB Unwind Inc (BINDQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of DNIB Unwind Inc (BINDQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

DNIB Unwind Inc (BINDQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

DNIB Unwind Inc Insider Transactions

No Available Data

What does Acceleron Pharma Inc do?

Who are the key executives at Acceleron Pharma Inc?

Noubar Afeyan is the 10 percent owner of Acceleron Pharma Inc. Other key executives at Acceleron Pharma Inc include EVP & Chief Commercial Officer Sujay Kango , SVP & CFO and Treasurer Kevin F Mclaughlin , and SVP & General Counsel and Sec. Adam M Veness .

Acceleron Pharma Inc (XLRN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Acceleron Pharma Inc (XLRN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Acceleron Pharma Inc (XLRN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Acceleron Pharma Inc (XLRN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Acceleron Pharma Inc Insider Transactions

No Available Data

What does Tetraphase Pharmaceuticals Inc do?

Who are the key executives at Tetraphase Pharmaceuticals Inc?

Noubar Afeyan is the 10 percent owner of Tetraphase Pharmaceuticals Inc. Other key executives at Tetraphase Pharmaceuticals Inc include director & See Remarks Larry G. Edwards , director & 10 percent owner Steven Boyd , and director & 10 percent owner Armistice Capital Master Fund Ltd. .

Tetraphase Pharmaceuticals Inc (TTPH) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Tetraphase Pharmaceuticals Inc (TTPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Tetraphase Pharmaceuticals Inc (TTPH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Tetraphase Pharmaceuticals Inc (TTPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tetraphase Pharmaceuticals Inc Insider Transactions

No Available Data

What does Agenus Inc do?

Who are the key executives at Agenus Inc?

Noubar Afeyan is the director of Agenus Inc. Other key executives at Agenus Inc include Chairman & CEO Garo H Armen , Chief Medical Officer Steven J O'day , and VP Finance Christine M Klaskin .

Agenus Inc (AGEN) Insider Trades Summary

Over the past 18 months, Noubar Afeyan made no insider transaction in Agenus Inc (AGEN). Other recent insider transactions involving Agenus Inc (AGEN) include a net purchase of 500,000 shares made by Garo H Armen , and a net purchase of 25,000 shares made by Ulf Wiinberg .

In summary, during the past 3 months, insiders sold 0 shares of Agenus Inc (AGEN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Agenus Inc (AGEN) were sold and 26,250 shares were bought by its insiders, resulting in a net purchase of 26,250 shares.

Agenus Inc (AGEN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Agenus Inc Insider Transactions

No Available Data

What does Sana Biotechnology Inc do?

Who are the key executives at Sana Biotechnology Inc?

Noubar Afeyan is the 10 percent owner of Sana Biotechnology Inc. Other key executives at Sana Biotechnology Inc include director & Head of SanaX Richard Mulligan , 10 percent owner Keith Crandell , and 10 percent owner Arch Venture Fund X Overage, L.p. .

Sana Biotechnology Inc (SANA) Insider Trades Summary

Over the past 18 months, Noubar Afeyan made no insider transaction in Sana Biotechnology Inc (SANA). Other recent insider transactions involving Sana Biotechnology Inc (SANA) include a net purchase of 1,818,181 shares made by Arch Venture Fund X Overage, L.p. , a net purchase of 1,818,181 shares made by Keith Crandell , and a net purchase of 1,818,181 shares made by Robert Nelsen .

In summary, during the past 3 months, insiders sold 0 shares of Sana Biotechnology Inc (SANA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 400,000 shares of Sana Biotechnology Inc (SANA) were sold and 5,454,543 shares were bought by its insiders, resulting in a net purchase of 5,054,543 shares.

Sana Biotechnology Inc (SANA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sana Biotechnology Inc Insider Transactions

No Available Data

What does Sigilon Therapeutics Inc do?

Who are the key executives at Sigilon Therapeutics Inc?

Noubar Afeyan is the 10 percent owner of Sigilon Therapeutics Inc. Other key executives at Sigilon Therapeutics Inc include 10 percent owner Lilly Eli & Co , 10 percent owner Shenandoah Acquisition Corp , and CHIEF OF STAFF AND CLO Matthew Paul Kowalsky .

Sigilon Therapeutics Inc (SGTX) Insider Trades Summary

Over the past 18 months, Noubar Afeyan made no insider transaction in Sigilon Therapeutics Inc (SGTX). Other recent insider transactions involving Sigilon Therapeutics Inc (SGTX) include a net purchase of 1,718,493 shares made by Lilly Eli & Co ,

In summary, during the past 3 months, insiders sold 0 shares of Sigilon Therapeutics Inc (SGTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sigilon Therapeutics Inc (SGTX) were sold and 1,718,493 shares were bought by its insiders, resulting in a net purchase of 1,718,493 shares.

Sigilon Therapeutics Inc (SGTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sigilon Therapeutics Inc Insider Transactions

No Available Data

What does Omega Therapeutics Inc do?

Who are the key executives at Omega Therapeutics Inc?

Noubar Afeyan is the director & 10 percent owner of Omega Therapeutics Inc. Other key executives at Omega Therapeutics Inc include director & 10 percent owner Richard A Young , 10 percent owner Flagship Pioneering Fund Vii General Partner Llc , and 10 percent owner Flagship Pioneering Fund Vii, L.p. .

Omega Therapeutics Inc (OMGA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Omega Therapeutics Inc (OMGA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Omega Therapeutics Inc (OMGA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Omega Therapeutics Inc (OMGA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Omega Therapeutics Inc Insider Transactions

No Available Data

What does CARISMA Therapeutics Inc do?

Who are the key executives at CARISMA Therapeutics Inc?

Noubar Afeyan is the 10 percent owner of CARISMA Therapeutics Inc. Other key executives at CARISMA Therapeutics Inc include 10 percent owner Modernatx, Inc. , Chief Scientific Officer Michael Klichinsky , and director & President and CEO Steven Kelly .

CARISMA Therapeutics Inc (CARM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of CARISMA Therapeutics Inc (CARM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of CARISMA Therapeutics Inc (CARM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

CARISMA Therapeutics Inc (CARM)'s detailed insider trading history can be found in Insider Trading Tracker table.

CARISMA Therapeutics Inc Insider Transactions

No Available Data

Noubar Afeyan Mailing Address

Above is the net worth, insider trading, and ownership report for Noubar Afeyan. You might contact Noubar Afeyan via mailing address: C/o Flagship Pioneering, Inc., 55 Cambridge Parkway, Suite 800e, Cambridge Ma 02142.

Discussions on Noubar Afeyan

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.